Australia Markets closed

PMV Pharmaceuticals, Inc. (PMVP)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.06+0.20 (+4.12%)
At close: 04:00PM EDT
5.06 0.00 (0.00%)
After hours: 04:01PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.86
Open4.91
Bid4.95 x 900
Ask7.88 x 1100
Day's range4.87 - 5.26
52-week range4.84 - 22.90
Volume496,471
Avg. volume664,870
Market cap231.067M
Beta (5Y monthly)0.96
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    PMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate Highlights

    Continued progress in ongoing Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation; PMV expects to provide next clinical update in 2H 2023Enrolled first patient in combination arm of the PYNNACLE study with PC14586 and KEYTRUDA® (pembrolizumab)Cash, cash equivalents, and marketable securities of $243.5 million as of December 31, 2022 PRINCETON, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- PMV

  • GlobeNewswire

    PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in March

    PRINCETON, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer, will participate at the following investor conferences in March. Cowen’s 43rd Annual Health Care Conference (March 6-8, 2023)Format:Tumor Diagnostic Development Corporate PanelDate:W

  • GlobeNewswire

    PMV Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference

    CRANBURY, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President & Chief Executive Officer of PMV Pharmaceuticals, will participate in a virtual fireside chat at the 5th Annual Evercore ISI HealthCONx Conference, taking place November 29 – December 1, 2022. The company will al